Abstract
Imaging biomarkers have a potential to identify key metabolic pathways that are up-regulated in cancer cells compared to normal cells. In early drug development, they can provide valuable information on the dissemination of the drug and estimate whether the drug reaches the target and, consequently, to determine the appropriate clinical benefit. The use of imaging as an early surrogate biomarker of response is also appealing, since it allows to tailor treatment regimens in individual patients. The aim of this review is to describe various imaging biomarkers covering most important cancer hallmarks such as cell death, proliferation, metabolism, vascularity, and hypoxia. We highlight the current status of using molecular imaging such as fluorodeoxyglucose (FDG), fluorothymidine (FLT), fluoromisonidazole (FMISO), and fluoroazomycin arabinoside (FAZA) positron emission tomography (PET) as well as advanced magnetic resonance imaging (MRI) techniques such as dynamic contrast enhancing (DCE) and diffusion weighted (DW)-MRI, and their potential roles in cancer drug development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
